Recombinant clostridial neurotoxins with increased duration of effect

Patent metadata

Field	Value
Publication number	US-10603353-B2
Application number	US-201615735417-A
Country	US
Kind code	B2
Filing date	Jun 10, 2016
Priority date	Jun 11, 2015
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.

First claim

The invention claimed is:

1. A recombinant clostridial neurotoxin comprising a protein segment consisting of at least 50 amino acid residues, wherein said protein segment consists of the amino acid sequence (Xaa) x -[(P,A,S) y -(Xaa)-] z (P,A,S) y -(Xaa) x , wherein Xaa is an amino acid residue independently selected from any naturally occurring amino acid residue, provided that at least one Xaa in [(P,A,S) y -(Xaa)-] z is different from an alanine, serine or proline residue; (P,A,S) represents an amino acid residue independently selected from an alanine (A), a serine (S) and a proline (P) residue; x is a number independently selected from 0 and 1; y is a number independently selected from 3 and 4; and z is 9 or more.

2. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment comprises an amino acid sequence consisting of between 50 and 3000 amino acid residues.

3. The recombinant clostridial neurotoxin of claim 1 , wherein the proline residues comprised in said protein segment constitute more than 4% and less than 40% of the amino acids of said protein segment.

4. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment comprises at least one amino acid sequence selected from the group consisting of: (VPASA) 20 (SEQ ID NO: 12) and (VAPSA) 20 (SEQ ID NO: 13); or circular permuted versions or (a) multimer(s) of these sequences as a whole or parts of these sequences.

5. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment is inserted at (i) the N-terminus of the light chain of said recombinant clostridial neurotoxin; (ii) the C-terminus of the light chain of said recombinant clostridial neurotoxin; (iii) the N-terminus of the heavy chain of said recombinant clostridial neurotoxin; or (iv) the C-terminus of the heavy chain of said recombinant clostridial neurotoxin.

6. The recombinant clostridial neurotoxin of claim 1 , wherein the sequence of said clostridial neurotoxin is selected from the sequence of (i) a Clostridium botulinum neurotoxin serotype A, B, C, D, E, F, and G, (ii) a functional variant of a Clostridium botulinum neurotoxin of (i), or (iii) a chimeric Clostridium botulinum neurotoxin, wherein the clostridial neurotoxin light chain and heavy chain are from different clostridial neurotoxin serotypes.

7. The recombinant clostridial neurotoxin of claim 1 , wherein said recombinant clostridial neurotoxin shows increased duration of effect relative to an identical clostridial neurotoxin without said protein segment.

8. The recombinant clostridial neurotoxin of claim 1 , wherein the recombinant clostridial neurotoxin causes longer lasting denervation relative to an identical clostridial neurotoxin without said protein segment.

9. A pharmaceutical composition comprising the recombinant clostridial neurotoxin of claim 1 .

10. A method for cosmetic treatment comprising administering a recombinant clostridial neurotoxin of claim 1 to a patient in need thereof.

11. A method for the generation of a recombinant clostridial neurotoxin, said method comprising obtaining a recombinant nucleic acid sequence encoding a recombinant single-chain precursor clostridial neurotoxin by the insertion of a nucleic acid sequence encoding the protein segment according to claim 1 into a nucleic acid sequence encoding a parental clostridial neurotoxin.

12. A recombinant single-chain clostridial neurotoxin precursor for a disulfide-linked di-chain clostridial neurotoxin, comprising a functionally active clostridial neurotoxin light chain, a functionally active neurotoxin heavy chain, a loop region linking the C-terminus of the light chain with the N-terminus of the heavy chain, and protein segment as defined in claim 1 .

13. A nucleic acid sequence encoding the recombinant single-chain clostridial neurotoxin of claim 12 .

14. A method for obtaining the nucleic acid sequence of claim 13 , comprising inserting a nucleic acid sequence encoding said protein segment into a nucleic acid sequence encoding a parental clostridial neurotoxin.

15. A vector comprising the nucleic acid sequence of claim 13 , or the nucleic acid sequence obtainable by a method comprising inserting a nucleic acid sequence encoding said protein segment into a nucleic acid sequence encoding a parental clostridial neurotoxin.

16. A recombinant host cell comprising the nucleic acid sequence of claim 13 , the nucleic acid sequence obtainable by the method comprising inserting a nucleic acid sequence encoding said protein segment into a nucleic acid sequence encoding a parental clostridial neurotoxin, or a vector comprising said sequence.

17. A method for producing the recombinant single-chain precursor clostridial neurotoxin of claim 12 , comprising expressing a nucleic acid sequence encoding the recombinant single-chain clostridial neurotoxin.

18. The recombinant clostridial neurotoxin of claim 1 , wherein Xaa is valine and wherein z is a number between 9 and 750.

19. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment comprises an amino acid sequence consisting of between 90 and 220 amino acid residues.

20. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment comprises (VPASA) 20 (SEQ ID NO: 12).

21. The recombinant clostridial neurotoxin of claim 1 , wherein said protein segment is inserted at the N-terminus of the light chain of said recombinant clostridial neurotoxin.

22. The recombinant clostridial neurotoxin of claim 1 , wherein the sequence of said clostridial neurotoxin is the sequence of Clostridium botulinum neurotoxin serotype A.

23. The recombinant clostridial neurotoxin of claim 1 , wherein said recombinant clostridial neurotoxin has a light chain and a heavy chain comprised in the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15.

24. The method according to claim 11 , wherein said method further comprises heterologously expressing said recombinant nucleic acid sequence in a host cell.

25. The method according to claim 24 , wherein said host cell is a bacterial host cell.

26. The method according to claim 25 , wherein said bacterial host cell is Escherichia coli.

27. The recombinant single-chain clostridial neurotoxin precursor for a disulfide-linked di-chain clostridial neurotoxin of claim 12 , wherein the sequence of said clostridial neurotoxin is selected from the sequence of (i) a Clostridium botulinum neurotoxin serotype A, B, C, D, E, F, and G, (ii) a functional variant of a Clostridium botulinum neurotoxin of (i), or (iii) a chimeric Clostridium botulinum neurotoxin, wherein the clostridial neurotoxin light chain and heavy chain are from different clostridial neurotoxin serotypes.

Assignees

• Merz Pharma Gmbh & Co Kgaa

Inventors

• FREVERT Jürgen
• Hofmann Fred
• Schmidt Michael
• López De La Paz Manuela
• Scheps Daniel

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12Y304/24069

  Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12Y304/24068

  Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin · CPC title

• C07K14/33

  from Clostridium (G) · CPC title